首页 > 最新文献

Magyar onkologia最新文献

英文 中文
[Photon field junction for external beam radiotherapy of breast cancer involving axillary and supraclavicular lymph nodes]. [涉及腋窝和锁骨上淋巴结的乳腺癌体外放射治疗的光子场连接]。
Pub Date : 2024-07-16 Epub Date: 2024-06-04
Szilvia Gazdag-Hegyesi, Ádám Gáldi, Tamás Pócza, Tibor Major, Zoltán Takácsi Nagy, Csilla Pesznyák

We present evaluation of junction of coplanar external beam photon fields and its portal dosimetric analysis for breast cancer with positive lymph nodes. In our work, we compared twelve patients affected by breast cancer with axillary and supraclavicular lymph nodes, using conformal external beam plans from a dosimetric point of view. 3-3 plans were prepared per patient. Three methods were used for the conformal technique to investigate the potential of lymph nodes treatment field's collimations. During the evaluation of the portal dosimetry images, it was concluded that the junction plane at isocenter appeared as a discrete coldline, when fitted the regional field with or without collimation manually and by the software. However, the coverage of the isocenter plane is strongly influenced by the linear accelerator and the fitted field edges. Based on our results, in order to avoid uncertainties arising from field junctions and the overdosed areas of the target volume, it is more appropriate to choose another advanced irradiation technique such as intensity-modulated radiation therapy.

我们介绍了共面外照射光子场交界处的评估及其针对淋巴结阳性乳腺癌的门户剂量学分析。在我们的工作中,我们从剂量学的角度对 12 名患有腋窝和锁骨上淋巴结的乳腺癌患者进行了比较,并使用了共形外照射计划。每位患者准备了 3-3 个计划。共形技术使用了三种方法来研究淋巴结治疗场准直的潜力。在评估门静脉剂量测定图像时,得出的结论是,当用手动或软件拟合有准直或无准直的区域野时,等中心的交界平面显示为一条不连续的冷线。不过,等中心平面的覆盖范围受直线加速器和拟合场边缘的影响很大。根据我们的研究结果,为了避免场交界处和靶体积过剂量区带来的不确定性,选择另一种先进的辐照技术(如调强放射治疗)更为合适。
{"title":"[Photon field junction for external beam radiotherapy of breast cancer involving axillary and supraclavicular lymph nodes].","authors":"Szilvia Gazdag-Hegyesi, Ádám Gáldi, Tamás Pócza, Tibor Major, Zoltán Takácsi Nagy, Csilla Pesznyák","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We present evaluation of junction of coplanar external beam photon fields and its portal dosimetric analysis for breast cancer with positive lymph nodes. In our work, we compared twelve patients affected by breast cancer with axillary and supraclavicular lymph nodes, using conformal external beam plans from a dosimetric point of view. 3-3 plans were prepared per patient. Three methods were used for the conformal technique to investigate the potential of lymph nodes treatment field's collimations. During the evaluation of the portal dosimetry images, it was concluded that the junction plane at isocenter appeared as a discrete coldline, when fitted the regional field with or without collimation manually and by the software. However, the coverage of the isocenter plane is strongly influenced by the linear accelerator and the fitted field edges. Based on our results, in order to avoid uncertainties arising from field junctions and the overdosed areas of the target volume, it is more appropriate to choose another advanced irradiation technique such as intensity-modulated radiation therapy.</p>","PeriodicalId":94127,"journal":{"name":"Magyar onkologia","volume":"68 2","pages":"163-168"},"PeriodicalIF":0.0,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Examination of breast density in breast cancer discordant twin pairs]. [乳腺癌不一致双胞胎的乳房密度检查]。
Pub Date : 2024-07-16 Epub Date: 2024-07-14
Szilárd Veres, Fruzsina Martinovszky, Márk Di Giovanni, Bettina Budai, Beatrix Beszedics, István Szabó, Henriett Butz, Attila Patócs, Bálint Török, Mátyás Ujlaki, László Dávid Tárnoki, Domonkos Ádám Tárnoki

Previous twin studies show that genetic factors are responsible for 63% of the variability in breast density. We analyzed the mammographic images of 9 discordant twin pairs for breast cancer from the population-based Hungarian Twin Registry. We measured breast density using 3D Slicer software. Genetic variants predisposing to breast cancer were also examined. One of the examined twin pairs had a BRCA2 mutation in both members. There was no significant difference between the mean values of breast density in the tumor and non-tumor groups (p=0.323). In terms of parity and the presence of menopause, we found mostly no significant difference between the members of the twin pair. In our cohort of identical twins discordant for breast cancer, the average breast density showed no significant difference, which can be explained by the common genetic basis of breast cancer and breast density.

以往的双胞胎研究表明,遗传因素占乳腺密度变异的 63%。我们分析了来自匈牙利双生子登记处的 9 对乳腺癌不和双生子的乳房X光图像。我们使用 3D Slicer 软件测量了乳房密度。我们还研究了易患乳腺癌的基因变异。其中一对受检双胞胎的两名成员都有 BRCA2 基因突变。肿瘤组和非肿瘤组的乳腺密度平均值无明显差异(P=0.323)。在同卵双生和是否绝经方面,我们发现孪生姐妹之间大多没有明显差异。在我们的同卵双胞胎队列中,乳腺癌不一致的同卵双胞胎的平均乳房密度没有明显差异,这可以用乳腺癌和乳房密度的共同遗传基础来解释。
{"title":"[Examination of breast density in breast cancer discordant twin pairs].","authors":"Szilárd Veres, Fruzsina Martinovszky, Márk Di Giovanni, Bettina Budai, Beatrix Beszedics, István Szabó, Henriett Butz, Attila Patócs, Bálint Török, Mátyás Ujlaki, László Dávid Tárnoki, Domonkos Ádám Tárnoki","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Previous twin studies show that genetic factors are responsible for 63% of the variability in breast density. We analyzed the mammographic images of 9 discordant twin pairs for breast cancer from the population-based Hungarian Twin Registry. We measured breast density using 3D Slicer software. Genetic variants predisposing to breast cancer were also examined. One of the examined twin pairs had a BRCA2 mutation in both members. There was no significant difference between the mean values of breast density in the tumor and non-tumor groups (p=0.323). In terms of parity and the presence of menopause, we found mostly no significant difference between the members of the twin pair. In our cohort of identical twins discordant for breast cancer, the average breast density showed no significant difference, which can be explained by the common genetic basis of breast cancer and breast density.</p>","PeriodicalId":94127,"journal":{"name":"Magyar onkologia","volume":"68 2","pages":"171-176"},"PeriodicalIF":0.0,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Mutation frequency of homologous recombination repair genes in prostate adenocarcinomas]. [前列腺癌中同源重组修复基因的突变频率]。
Pub Date : 2024-07-16 Epub Date: 2024-06-04
Zsombor Melegh, Erzsébet Csernák, Andrea Kohánka, Mónika Rubovszkyné Gallai, Eszter Bencze, Melinda Szőke, Luca Pap, Andrea Simon, Zsófia Küronya, Krisztina Biró, Lajos Géczi, Erika Tóth

The best predictive marker for the expected efficacy of PARP inhibitor therapy is mutations in BRCA1/2 or other homologous recombination repair genes. These tests are part of routine molecular pathology diagnostics. Among 281 patients with prostate adenocarcinoma, somatic pathogenic mutations in one of these genes were identified in 21.4% of patients. In 28.5% of the patients, the test was unsuccessful; the main limitation of successful testing was the age of the paraffin blocks and low DNA concentration. In the case of BRCA1/2 testing, the success rate was significantly reduced for samples older than 5 years, while in tests involving a broader set of homologous recombination repair genes, the success rate was significantly reduced for samples older than 2 years. Therefore, it is very important to test high-risk prostate cancers at the time of primary diagnosis, and probably also liquid biopsy testing of circulating tumor DNA will play an important role in safe diagnosis in the near future.

PARP 抑制剂疗法预期疗效的最佳预测指标是 BRCA1/2 或其他同源重组修复基因的突变。这些检测是常规分子病理学诊断的一部分。在 281 名前列腺癌患者中,21.4% 的患者发现了其中一个基因的体细胞致病突变。28.5%的患者检测不成功;检测成功的主要限制因素是石蜡块的年龄和 DNA 浓度较低。在 BRCA1/2 检测中,5 年以上样本的成功率明显降低,而在涉及更多同源重组修复基因的检测中,2 年以上样本的成功率明显降低。因此,在初诊时对高风险前列腺癌进行检测非常重要,在不久的将来,循环肿瘤 DNA 的液体活检检测也可能在安全诊断中发挥重要作用。
{"title":"[Mutation frequency of homologous recombination repair genes in prostate adenocarcinomas].","authors":"Zsombor Melegh, Erzsébet Csernák, Andrea Kohánka, Mónika Rubovszkyné Gallai, Eszter Bencze, Melinda Szőke, Luca Pap, Andrea Simon, Zsófia Küronya, Krisztina Biró, Lajos Géczi, Erika Tóth","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The best predictive marker for the expected efficacy of PARP inhibitor therapy is mutations in BRCA1/2 or other homologous recombination repair genes. These tests are part of routine molecular pathology diagnostics. Among 281 patients with prostate adenocarcinoma, somatic pathogenic mutations in one of these genes were identified in 21.4% of patients. In 28.5% of the patients, the test was unsuccessful; the main limitation of successful testing was the age of the paraffin blocks and low DNA concentration. In the case of BRCA1/2 testing, the success rate was significantly reduced for samples older than 5 years, while in tests involving a broader set of homologous recombination repair genes, the success rate was significantly reduced for samples older than 2 years. Therefore, it is very important to test high-risk prostate cancers at the time of primary diagnosis, and probably also liquid biopsy testing of circulating tumor DNA will play an important role in safe diagnosis in the near future.</p>","PeriodicalId":94127,"journal":{"name":"Magyar onkologia","volume":"68 2","pages":"137-141"},"PeriodicalIF":0.0,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Application of new imaging modalities for brachytherapy of cancer patients]. [癌症患者近距离放射治疗中新成像模式的应用]。
Pub Date : 2024-07-16 Epub Date: 2024-04-22
Tibor Major, Júlia Vizkeleti, Péter Ágoston, Zoltán Takácsi-Nagy, Csaba Polgár

In the Radiotherapy Centre of the National Institute of Oncology, Budapest, a 0.55 T MR scanner (MAGNETOM Free. Max) and a ring-like X-ray machine (ImagingRing) have been in operation since 2022. The MR scanner has a tunnel diameter of 80 cm, the X-ray machine has a ring diameter of 121 cm. The latter can also be used for cone-beam CT (CBCT) imaging. The MR scanner is mainly used for planning gynaecological brachytherapy (BT) treatments. Image distortions in MR imaging were investigated with a special grid phantom. After head and neck and breast implant, image quality of ImagingRing CBCT and planning CT was compared. The position of the radiation source was verified by radiographs taken during treatment. Despite the lower field strength, the image quality of the MR scanner was found to be adequate for treatment planning of gynaecological BT. Image distortions were found to be clinically negligible. On CBCT images obtained with ImagingRing, catheters could always be well identified, and anatomical organs were adequately visualized for head and neck treatments, but not for breast implants. The MR scanner is suitable for treatment planning for gynaecological BT due to its good image quality and low image distortion. The image quality of the ImagingRing is suitable for treatment planning for small body sizes, but not for larger sizes. The device can be used to in vivo check of the radiation source position during treatment.

在布达佩斯国家肿瘤研究所的放射治疗中心,一台 0.55 T MR 扫描仪(MAGNETOM Free. Max)和一台环形 X 光机(ImagingRing)自 2022 年起开始运行。磁共振扫描仪的通道直径为 80 厘米,X 光机的环形直径为 121 厘米。后者还可用于锥束 CT(CBCT)成像。磁共振扫描仪主要用于规划妇科近距离放射治疗(BT)。通过一个特殊的网格模型对 MR 成像中的图像失真进行了研究。在头颈部和乳房植入后,对 ImagingRing CBCT 和计划 CT 的图像质量进行了比较。辐射源的位置通过治疗过程中拍摄的照片进行了验证。尽管磁场强度较低,但磁共振扫描仪的图像质量仍足以用于妇科 BT 的治疗规划。图像失真在临床上可以忽略不计。在使用 ImagingRing 获得的 CBCT 图像上,导管总是能很好地识别,头颈部治疗的解剖器官也能充分显现,但乳房植入物却不能。磁共振扫描仪的图像质量好,图像失真度低,因此适用于妇科 BT 的治疗规划。ImagingRing 的图像质量适用于小体型的治疗规划,但不适用于大体型。该设备可用于治疗过程中放射源位置的活体检查。
{"title":"[Application of new imaging modalities for brachytherapy of cancer patients].","authors":"Tibor Major, Júlia Vizkeleti, Péter Ágoston, Zoltán Takácsi-Nagy, Csaba Polgár","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In the Radiotherapy Centre of the National Institute of Oncology, Budapest, a 0.55 T MR scanner (MAGNETOM Free. Max) and a ring-like X-ray machine (ImagingRing) have been in operation since 2022. The MR scanner has a tunnel diameter of 80 cm, the X-ray machine has a ring diameter of 121 cm. The latter can also be used for cone-beam CT (CBCT) imaging. The MR scanner is mainly used for planning gynaecological brachytherapy (BT) treatments. Image distortions in MR imaging were investigated with a special grid phantom. After head and neck and breast implant, image quality of ImagingRing CBCT and planning CT was compared. The position of the radiation source was verified by radiographs taken during treatment. Despite the lower field strength, the image quality of the MR scanner was found to be adequate for treatment planning of gynaecological BT. Image distortions were found to be clinically negligible. On CBCT images obtained with ImagingRing, catheters could always be well identified, and anatomical organs were adequately visualized for head and neck treatments, but not for breast implants. The MR scanner is suitable for treatment planning for gynaecological BT due to its good image quality and low image distortion. The image quality of the ImagingRing is suitable for treatment planning for small body sizes, but not for larger sizes. The device can be used to in vivo check of the radiation source position during treatment.</p>","PeriodicalId":94127,"journal":{"name":"Magyar onkologia","volume":"68 2","pages":"155-162"},"PeriodicalIF":0.0,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[County differences in incidence and mortality of malignant neoplasms in Hungary between 2005 and 2019]. [2005 至 2019 年匈牙利恶性肿瘤发病率和死亡率的县域差异]。
Pub Date : 2024-07-16 Epub Date: 2024-04-30
András Wéber, István Szatmári, Mária Dobozi, Zsuzsanna Kéki, Lászlóné Hilbert, Gabriella Géczy Branyiczkiné, Péter Nagy, Csaba Polgár, István Kenessey

The objective of our study was to map county differences in incidence and mortality by cancers and examine their changes over time. Based on the database of National Cancer Registry and Central Statistical Office, age-standardized incidence and mortality rates per 100,000 person-years were calculated for each county for 15 cancer types and 3 time periods. East-West divide was apparent in incidence and mortality of lung cancer, with larger weight in East (Borsod-Abaúj-Zemplén, Heves, Jász-Nagykun-Szolnok, Békés counties). Concentration of lip and oral cavity malignancies was identified in the northeastern periphery (Borsod-Abaúj-Zemplén, Szabolcs-Szatmár-Bereg counties). Breast cancer incidence was the highest in Budapest. As a conclusion, changes in cancer incidence and mortality over time were similar to developed countries; however, values were higher. Differences in spatial distribution follow territorial pattern of social deprivation, which correspond to higher prevalence of health risk factors. Our study contributes to planning of public health programs by pinpointing regional inequalities in different cancer types.

我们的研究旨在绘制各县癌症发病率和死亡率的差异图,并研究其随时间的变化。根据国家癌症登记处和中央统计局的数据库,计算了每个县 15 种癌症和 3 个时期每 10 万人年的年龄标准化发病率和死亡率。肺癌的发病率和死亡率存在明显的东西差异,东部(博尔索德-阿巴乌伊-岑普勒恩、赫韦斯、雅斯-纳吉昆-索尔诺克、贝凯斯等县)的比重较大。唇部和口腔恶性肿瘤主要集中在东北部周边地区(Borsod-Abaúj-Zemplén 县、Szabolcs-Szatmár-Bereg 县)。布达佩斯的乳腺癌发病率最高。总之,随着时间的推移,癌症发病率和死亡率的变化与发达国家相似,但数值更高。空间分布的差异遵循社会贫困的地域模式,与较高的健康风险因素流行率相对应。我们的研究通过指出不同癌症类型的地区不平等现象,为公共卫生计划的规划做出了贡献。
{"title":"[County differences in incidence and mortality of malignant neoplasms in Hungary between 2005 and 2019].","authors":"András Wéber, István Szatmári, Mária Dobozi, Zsuzsanna Kéki, Lászlóné Hilbert, Gabriella Géczy Branyiczkiné, Péter Nagy, Csaba Polgár, István Kenessey","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The objective of our study was to map county differences in incidence and mortality by cancers and examine their changes over time. Based on the database of National Cancer Registry and Central Statistical Office, age-standardized incidence and mortality rates per 100,000 person-years were calculated for each county for 15 cancer types and 3 time periods. East-West divide was apparent in incidence and mortality of lung cancer, with larger weight in East (Borsod-Abaúj-Zemplén, Heves, Jász-Nagykun-Szolnok, Békés counties). Concentration of lip and oral cavity malignancies was identified in the northeastern periphery (Borsod-Abaúj-Zemplén, Szabolcs-Szatmár-Bereg counties). Breast cancer incidence was the highest in Budapest. As a conclusion, changes in cancer incidence and mortality over time were similar to developed countries; however, values were higher. Differences in spatial distribution follow territorial pattern of social deprivation, which correspond to higher prevalence of health risk factors. Our study contributes to planning of public health programs by pinpointing regional inequalities in different cancer types.</p>","PeriodicalId":94127,"journal":{"name":"Magyar onkologia","volume":"68 2","pages":"95-112"},"PeriodicalIF":0.0,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The pitfalls of lung cancer coding practices based on the evaluation of the National Cancer Registry]. [基于全国癌症登记处评估的肺癌编码实践陷阱]。
Pub Date : 2024-07-16 Epub Date: 2024-05-24
Petra Parrag, Mária Dobozi, István Szatmári, András Wéber, Péter Nagy, Csaba Polgár, István Kenessey

The quality of input data determines the reliability of epidemiological assessments. Thus, the verification of cases reported to the National Cancer Registry is required. The objective of our study was evaluating the reliability of cases diagnosed by lung cancer, exploring the patterns of erroneous reports. The validation of the 11,750 lung cancer cases reported to the Cancer Registry in 2018 was performed with the involvement of the recording hospitals, analyzing the characteristics of reports by gender, age and attributes of the reporting institutions. 81.3 percent of the reported cases was confirmed, in 40.4 percent of the false reports, malignancy was not present at all. Among the erroneous cases women and the elderly age group were overrepresented. The highest deleted rate occurred in Borsod- Abaúj-Zemplén county. As a conclusion, there is a strong need for the improvement of the efficiency in encoding lung cancer. The most common errors: confusion of malignant-benign, cancerous-non-cancerous and primary-metastatic lesions. The reliability is not affected by the role of individual institutions in the hierarchy of health care. The availability of reliable epidemiological data is crucial in the fight against cancer, which requires broad professional cooperation.

输入数据的质量决定了流行病学评估的可靠性。因此,需要对向全国癌症登记处报告的病例进行核实。我们的研究旨在评估肺癌诊断病例的可靠性,探索错误报告的模式。在记录医院的参与下,对2018年上报至癌症登记处的11750例肺癌病例进行了验证,按性别、年龄和上报机构的属性分析了报告的特征。81.3%的报告病例得到证实,40.4%的虚假报告中根本不存在恶性肿瘤。在误报病例中,女性和老年人的比例较高。博索德-阿巴伊-岑普伦县的删除率最高。总之,亟需提高肺癌的编码效率。最常见的错误:混淆了恶性-良性、癌性-非癌性和原发-转移病灶。可靠性并不受医疗保健等级制度中各机构角色的影响。获得可靠的流行病学数据对于抗击癌症至关重要,这需要广泛的专业合作。
{"title":"[The pitfalls of lung cancer coding practices based on the evaluation of the National Cancer Registry].","authors":"Petra Parrag, Mária Dobozi, István Szatmári, András Wéber, Péter Nagy, Csaba Polgár, István Kenessey","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The quality of input data determines the reliability of epidemiological assessments. Thus, the verification of cases reported to the National Cancer Registry is required. The objective of our study was evaluating the reliability of cases diagnosed by lung cancer, exploring the patterns of erroneous reports. The validation of the 11,750 lung cancer cases reported to the Cancer Registry in 2018 was performed with the involvement of the recording hospitals, analyzing the characteristics of reports by gender, age and attributes of the reporting institutions. 81.3 percent of the reported cases was confirmed, in 40.4 percent of the false reports, malignancy was not present at all. Among the erroneous cases women and the elderly age group were overrepresented. The highest deleted rate occurred in Borsod- Abaúj-Zemplén county. As a conclusion, there is a strong need for the improvement of the efficiency in encoding lung cancer. The most common errors: confusion of malignant-benign, cancerous-non-cancerous and primary-metastatic lesions. The reliability is not affected by the role of individual institutions in the hierarchy of health care. The availability of reliable epidemiological data is crucial in the fight against cancer, which requires broad professional cooperation.</p>","PeriodicalId":94127,"journal":{"name":"Magyar onkologia","volume":"68 2","pages":"115-123"},"PeriodicalIF":0.0,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Incidentally discovered ectopic tissue in the central neck region (level VI) of the neck - A case series, retrospective analysis and literature review]. [偶然发现的颈部中央区域(VI 级)异位组织--病例系列、回顾性分析和文献综述]。
Pub Date : 2024-07-16 Epub Date: 2024-04-22
Bernadett Lévay, Ilona Péter, Georgina Fröhlich, Pál Koltai, Gabriella Ivády, Balázs Járay, Péter Pogány, János Szőke, Erika Tóth, Nóra Udvarhelyi, Ferenc Oberna

The thymus derives from the third branchial pouch, which migrates to the mediastinum through the central region of the neck. During the migration, particles split off and develop separately. The prevalence of ectopic thymus is 20-40%. The purpose of this retrospective case series study was to investigate the prevalence of embryological tissue remnants in the central region, in patients treated for thyroid lesions. Between January 1 2018 and September 1 2020, 84 patients who underwent central neck dissection were selected. Clinicopathological data as age, gender, histopathological result and TNM stage were analyzed. Ectopic tissue in the central neck region was discovered in 28 cases. The prevalence of ectopic lesions showed increase in Stage I thyroid carcinomas. There was no significant correlation with patients' age, gender, or with the stage. We emphasize the clinicopathological role of ectopic tissues, which can occur in the central region of the neck.

胸腺源于第三支囊,通过颈部中央区域迁移到纵隔。在迁移过程中,颗粒会分裂并单独发育。异位胸腺的发病率为 20-40%。这项回顾性病例系列研究的目的是调查因甲状腺病变接受治疗的患者中央区胚胎组织残留的发生率。研究选取了2018年1月1日至2020年9月1日期间接受颈部中央切除术的84例患者。分析了年龄、性别、组织病理学结果和TNM分期等临床病理数据。结果发现,28 例患者的颈部中央区域存在异位组织。异位病变的发生率在I期甲状腺癌中有所增加。异位病变与患者的年龄、性别或分期无明显相关性。我们强调异位组织的临床病理作用,因为它可能发生在颈部中央区域。
{"title":"[Incidentally discovered ectopic tissue in the central neck region (level VI) of the neck - A case series, retrospective analysis and literature review].","authors":"Bernadett Lévay, Ilona Péter, Georgina Fröhlich, Pál Koltai, Gabriella Ivády, Balázs Járay, Péter Pogány, János Szőke, Erika Tóth, Nóra Udvarhelyi, Ferenc Oberna","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The thymus derives from the third branchial pouch, which migrates to the mediastinum through the central region of the neck. During the migration, particles split off and develop separately. The prevalence of ectopic thymus is 20-40%. The purpose of this retrospective case series study was to investigate the prevalence of embryological tissue remnants in the central region, in patients treated for thyroid lesions. Between January 1 2018 and September 1 2020, 84 patients who underwent central neck dissection were selected. Clinicopathological data as age, gender, histopathological result and TNM stage were analyzed. Ectopic tissue in the central neck region was discovered in 28 cases. The prevalence of ectopic lesions showed increase in Stage I thyroid carcinomas. There was no significant correlation with patients' age, gender, or with the stage. We emphasize the clinicopathological role of ectopic tissues, which can occur in the central region of the neck.</p>","PeriodicalId":94127,"journal":{"name":"Magyar onkologia","volume":"68 2","pages":"177-190"},"PeriodicalIF":0.0,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The pathological processing of prostate biopsy and resection specimens]. [前列腺活检和切除标本的病理处理]。
Pub Date : 2024-07-16 Epub Date: 2024-05-19
Zsombor Melegh, Kamilla Németh, Eszter Székely, Katalin Borka, Rita Bori, Dávid Semjén, Boglárka Pósfai, Farkas Sükösd, Ferenc Salamon, László Bidiga, Levente Kuthi

Prostate cancer stands as the most prevalent malignant tumor among men; with its incidence increasing with advancing age. The spectrum of patient care options for this disease is broad, encompassing approaches such as "active surveillance," definitive radiation therapy, robot-assisted surgery, among others. These diverse modalities afford opportunities for cure or successful management in the majority of cases. It is paramount to underscore that optimal treatment hinges upon a multidisciplinary framework, wherein the coordinated efforts of allied healthcare professionals yield the highest standard of patient care. Hence, it is imperative for pathologists to keep abreast of contemporary processing and specimen collection protocols, as well as the potential necessity of supplementary investigations and their clinical significance. The latest Hungarian guideline on prostate cancer care features a dedicated chapter delineating the pivotal role and responsibilities of pathologists. Through this discourse, we aim to consolidate and disseminate pertinent insights, thereby fostering the continuing enhancement of pathologists' knowledge and elucidating the intricacies of histological processing to our clinical counterparts.

前列腺癌是男性最常见的恶性肿瘤,发病率随着年龄的增长而增加。这种疾病的治疗方法多种多样,包括 "主动监测"、明确的放射治疗、机器人辅助手术等。这些不同的方法为治愈或成功控制大多数病例提供了机会。必须强调的是,最佳治疗取决于多学科框架,在这一框架下,联合医疗保健专业人员的协调努力将产生最高标准的患者护理。因此,病理学家必须及时了解现代处理和标本采集协议,以及补充检查的潜在必要性及其临床意义。匈牙利最新的前列腺癌治疗指南中专门有一章阐述了病理学家的关键作用和责任。通过这一讨论,我们旨在巩固和传播相关见解,从而促进病理学家知识的不断提高,并向临床同行阐明组织学处理的复杂性。
{"title":"[The pathological processing of prostate biopsy and resection specimens].","authors":"Zsombor Melegh, Kamilla Németh, Eszter Székely, Katalin Borka, Rita Bori, Dávid Semjén, Boglárka Pósfai, Farkas Sükösd, Ferenc Salamon, László Bidiga, Levente Kuthi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Prostate cancer stands as the most prevalent malignant tumor among men; with its incidence increasing with advancing age. The spectrum of patient care options for this disease is broad, encompassing approaches such as \"active surveillance,\" definitive radiation therapy, robot-assisted surgery, among others. These diverse modalities afford opportunities for cure or successful management in the majority of cases. It is paramount to underscore that optimal treatment hinges upon a multidisciplinary framework, wherein the coordinated efforts of allied healthcare professionals yield the highest standard of patient care. Hence, it is imperative for pathologists to keep abreast of contemporary processing and specimen collection protocols, as well as the potential necessity of supplementary investigations and their clinical significance. The latest Hungarian guideline on prostate cancer care features a dedicated chapter delineating the pivotal role and responsibilities of pathologists. Through this discourse, we aim to consolidate and disseminate pertinent insights, thereby fostering the continuing enhancement of pathologists' knowledge and elucidating the intricacies of histological processing to our clinical counterparts.</p>","PeriodicalId":94127,"journal":{"name":"Magyar onkologia","volume":"68 2","pages":"143-153"},"PeriodicalIF":0.0,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Immunomodulation in the tumor microenvironment: Therapeutic potential of combined inhibition of tumor hypoxia and PD-1/ PD-L1]. [肿瘤微环境中的免疫调节:联合抑制肿瘤缺氧和 PD-1/ PD-L1 的治疗潜力]。
Pub Date : 2024-07-16 Epub Date: 2024-06-03
Laura Svajda, Mihály Cserepes, Barbara Hegyi, Theodora Niczky, József Tóvári

Tumor hypoxia plays an important role in controlling tumor progression through signaling pathways related to the transcription factor HIF-1. In addition to enhancing migration, promoting angiogenesis and regulating metabolism, the hypoxic environment also affects immune function. In this hypoxic microenvironment an immunosuppressive milieu is established, where HIF-1 upregulates the expression of PD-L1, a key regulator of the immune response. We have found that elevated expression of PD-L1 correlates with increased HIF-1 levels in cancer cell lines and clinical samples. Thus, the co-inhibition of HIF-1 and PD-1/PD-L1 offers promising therapeutic possibilities. In this review we have examined the limitations of HIF-1 and PD-1/PD-L1 inhibition as monotherapy, explored their combined benefits and evaluated the feasibility of targeting PD-L1 with HIF-1 inhibitors.

肿瘤缺氧通过与转录因子 HIF-1 相关的信号通路在控制肿瘤进展方面发挥着重要作用。除了增强迁移、促进血管生成和调节新陈代谢外,缺氧环境还会影响免疫功能。在这种缺氧微环境中会形成一种免疫抑制环境,HIF-1 会上调免疫反应的关键调节因子 PD-L1 的表达。我们发现,在癌细胞系和临床样本中,PD-L1 表达的升高与 HIF-1 水平的升高相关。因此,共同抑制 HIF-1 和 PD-1/PD-L1 提供了有前景的治疗可能性。在这篇综述中,我们研究了单药抑制 HIF-1 和 PD-1/PD-L1 的局限性,探讨了它们的联合优势,并评估了用 HIF-1 抑制剂靶向 PD-L1 的可行性。
{"title":"[Immunomodulation in the tumor microenvironment: Therapeutic potential of combined inhibition of tumor hypoxia and PD-1/ PD-L1].","authors":"Laura Svajda, Mihály Cserepes, Barbara Hegyi, Theodora Niczky, József Tóvári","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Tumor hypoxia plays an important role in controlling tumor progression through signaling pathways related to the transcription factor HIF-1. In addition to enhancing migration, promoting angiogenesis and regulating metabolism, the hypoxic environment also affects immune function. In this hypoxic microenvironment an immunosuppressive milieu is established, where HIF-1 upregulates the expression of PD-L1, a key regulator of the immune response. We have found that elevated expression of PD-L1 correlates with increased HIF-1 levels in cancer cell lines and clinical samples. Thus, the co-inhibition of HIF-1 and PD-1/PD-L1 offers promising therapeutic possibilities. In this review we have examined the limitations of HIF-1 and PD-1/PD-L1 inhibition as monotherapy, explored their combined benefits and evaluated the feasibility of targeting PD-L1 with HIF-1 inhibitors.</p>","PeriodicalId":94127,"journal":{"name":"Magyar onkologia","volume":"68 2","pages":"126-135"},"PeriodicalIF":0.0,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The role of whole brain irradiation nowadays: more or less or different?] [如今全脑照射的作用:更多、更少还是不同?]
Pub Date : 2024-03-14 Epub Date: 2023-10-08
Ferenc Lakosi

In patients with poor performance status (KPS<50), ineligibility for effective systemic treatment and multiple brain metastases (BM) best supportive care is the preferred treatment over whole brain radiotherapy (WBRT). WBRT should be considered for the treatment of non-limited number (>4) brain metastases, depending on the patient's life expectancy, neurological symptoms, size, number and location of brain metastases, indication, type and availability of systemic therapy. In these patients if life expectancy is >4 months without small cell histology and without hippocampal lesions, hippocampal sparing WBRT with or without memantine is recommended. Simultaneous integrated boost for the BM is a logical and supportable concept. Prophylactic cranial irradiation (PCI) is still recommended in small cell lung cancer patients with complete remission. Hippocampal sparing WBRT needs further validation in this indication.

对于表现状态不佳(KPS4)的脑转移瘤患者,根据患者的预期寿命、神经系统症状、脑转移瘤的大小、数量和位置、适应症、全身治疗的类型和可用性而定。如果这些患者的预期寿命大于 4 个月,且没有小细胞组织学病变和海马病变,则推荐使用或不使用美金刚的海马疏松 WBRT。同时对脑干进行综合刺激是一个合理且可行的概念。对于完全缓解的小细胞肺癌患者,仍建议进行预防性头颅照射(PCI)。在这一适应症中,海马疏导WBRT需要进一步验证。
{"title":"[The role of whole brain irradiation nowadays: more or less or different?]","authors":"Ferenc Lakosi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In patients with poor performance status (KPS<50), ineligibility for effective systemic treatment and multiple brain metastases (BM) best supportive care is the preferred treatment over whole brain radiotherapy (WBRT). WBRT should be considered for the treatment of non-limited number (>4) brain metastases, depending on the patient's life expectancy, neurological symptoms, size, number and location of brain metastases, indication, type and availability of systemic therapy. In these patients if life expectancy is >4 months without small cell histology and without hippocampal lesions, hippocampal sparing WBRT with or without memantine is recommended. Simultaneous integrated boost for the BM is a logical and supportable concept. Prophylactic cranial irradiation (PCI) is still recommended in small cell lung cancer patients with complete remission. Hippocampal sparing WBRT needs further validation in this indication.</p>","PeriodicalId":94127,"journal":{"name":"Magyar onkologia","volume":"68 1","pages":"60-65"},"PeriodicalIF":0.0,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140133686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Magyar onkologia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1